Leveragen

Executive Summary

Leveragen, a private biotech headquartered in Cambridge, MA, specializes in genetic engineering to create next-generation genetic models that enable the discovery of diverse biologic modalities. Founded in 2018, the company has advanced to Phase 3 stage, focusing on developing comprehensive solutions for genetic modeling, including designer mutations to study gene function and disease mechanisms. By facilitating the development of novel diagnostics and therapeutics, Leveragen addresses critical needs in the biologics discovery space. Although financial details such as total funding and valuation are undisclosed, the company's progression to late-stage development suggests significant scientific traction and potential value creation.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Data Readout60% success
• Q2 2026Strategic Partnership with Major Pharma50% success
• Q3 2026Series B or C Financing Round70% success